Journal Article

Development of the paediatric society of the African league against rheumatism (PAFLAR) JIA registry and clinical profile of JIA in Africa from the PAFLAR JIA registry

Abushhaiwia, Awatif, Owusu, Sheila Agyeiwaa, Owino, Lawrence, Faleye, Ayodele, Elsehrawy, Gehad Gamal, Fazaa, Alia, Odhiambo, Rachel, Hashad, Soad, Abu-Zaid, Mohammed Hassan, Ferjani, Hanene, Kharrat, Lobna, Migowa, Angela Nyangore, Mosa, Doaa Mosad, Orwa, James, Nasef, Samah Ismail, Etayari, Hala, Eissa, Mervat, Hamdi, Wafa, Nessib, Dorra Ben

2024

Overview

Background The spectrum of Juvenile Idiopathic Arthritis (JIA) in Africa is still largely unknown. We thus set out to illustrate how we set up the PAFLAR JIA registry and describe the clinical profile of Juvenile Idiopathic Arthritis across various regions in Africa. Methods We carried out a retrospective observational cohort study where collaborators were trained on use of the existing PAFLAR REDCAP database to enter data for the JIA patients currently under their care capturing their epidemiological data, clinical features, laboratory investigations, diagnosis and therapy at initial diagnosis. Descriptive statistics including means, standard deviations, medians, interquartile ranges (IQR) for continuous variables and proportions for categorical variables were calculated as appropriate. Tests for difference between groups were performed between categorical variables using Pearson’s chi-square or Fisher’s exact tests. All analyses were performed using SPSS version 22 software. Results We enrolled 302 patients, 58.6% (177 of 302) of whom were female. The median age of disease onset was 7 years (range 3–11 years) and the median age at diagnosis was 8.5 years (range 5–12 years). The median duration delay in diagnosis was 6 months (range 1-20.8 months). The JIA categories included Systemic JIA 18.9% (57), Oligoarticular JIA 19.2% (83), Polyarticular RF + ve 5% (15), Polyarticular RF-ve 17.9% (54), Enthesitis Related Arthritis (ERA) 18.2% (55), Psoriatic Arthritis 7% (21) and undifferentiated JIA 5.6% (17). As regards treatment the commonest therapies were NSAID therapy at 31.1%, synthetic DMARDs at 18.1%, synthetic DMARDs combined with NSAIDs at 17.5% and steroid therapy at 9.6%. Biological DMARDs accounted for 2.3% of therapies offered to our patients at diagnosis. The average JADAS score was 10.3 (range 4.8–18.2) and the average CHAQ score was 1.3 (range 0.7-2.0). Conclusion Our study highlights strategies involved in setting up a Pan-African paediatric rheumatology registry that embraces our broad diversity and the vast spectrum of JIA in Africa while comparing the various therapies available to our patients. The PAFLAR JIA registry strives to ensure a comprehensive representation of the diverse healthcare landscapes within the continent. Further longitudinal observation studies are required to ascertain the long-term outcomes of our patients and ultimately help inform policy to create a more favorable health ecosystem to support the healthcare needs of JIA patients in Africa.

• Publisher: BioMed Central,BioMed Central Ltd,BMC
• Subject: Africa / Africa - epidemiology / Antirheumatic Agents - therapeutic use / Arthritis, Juvenile - diagnosis / Arthritis, Juvenile - drug therapy / Arthritis, Juvenile - epidemiology / Care and treatment / Child / Child, Preschool / Context Specific Paediatric Rheumatology Care-Lessons from Africa / Diagnosis / Epidemiology / Female / Global Health / Humans / Juvenile idiopathic arthritis / Male / Medicine / Medicine & Public Health / Paediatric rheumatology / Pediatrics / Registries / Research Article / Retrospective Studies / Rheumatoid arthritis in children / Rheumatology / Societies, Medical